Quince Therapeutics, Inc. (QNCX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$79.78M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$14.59M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$13.43M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$10.43M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$79.78M | (m) | (m) | (m) | $0.00* | -$18.89M* | (m) | $5.46M | (m) | $75.00K |
| 2026-03-31 | Reported | (m) | -$14.59M | (m) | (m) | (m) | $0.00 | -$7.63M | (m) | $6.84M | (m) | -$5.34M |
| 2025-09-30 | Reported | (m) | -$13.43M | (m) | (m) | (m) | $74.00K* | -$9.93M* | (m) | $8.08M | (m) | -$46.00K |
| 2025-06-30 | Reported | (m) | -$10.43M | (m) | (m) | (m) | $126.00K* | -$11.41M* | (m) | $6.55M | (m) | $67.00K |
| 2025-03-31 | Reported | (m) | -$14.86M | (m) | (m) | (m) | $148.00K | -$9.60M | (m) | $8.14M | (m) | $47.00K |
| 2024-09-30 | Reported | (m) | -$5.86M | (m) | (m) | (m) | $46.00K* | -$7.26M* | (m) | $4.92M | (m) | $13.00K |
| 2024-06-30 | Reported | (m) | -$28.19M | (m) | (m) | (m) | $39.00K* | -$8.74M* | (m) | $4.15M | (m) | $36.00K |
| 2024-03-31 | Reported | (m) | -$11.22M | (m) | (m) | (m) | $39.00K | -$8.35M | (m) | $3.70M | (m) | $31.00K |
| 2023-09-30 | Reported | (m) | -$6.09M | (m) | (m) | (m) | $0.00* | -$4.82M* | (m) | $1.43M | (m) | $0.00 |
| 2023-06-30 | Reported | (m) | -$5.58M | (m) | (m) | (m) | $0.00* | -$3.83M* | (m) | $1.35M | (m) | $0.00 |
| 2023-03-31 | Reported | (m) | -$12.96M | (m) | (m) | (m) | $136.00K | -$3.57M | (m) | $3.23M | (m) | -$248.00K |
| 2022-09-30 | Reported | (m) | -$7.62M | (m) | (m) | (m) | $50.00K* | -$6.70M* | (m) | $2.45M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$16.26M | (m) | (m) | (m) | $0.00* | -$15.41M* | (m) | $7.20M | (m) | -$284.00K |
| 2022-03-31 | Reported | (m) | -$21.86M | (m) | (m) | (m) | $5.00K | -$16.09M | (m) | $12.76M | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$21.68M | (m) | (m) | (m) | $0.00* | -$17.34M* | (m) | $14.04M | (m) | $0.00 |
| 2021-06-30 | Reported | (m) | -$21.78M | (m) | (m) | (m) | $99.00K* | -$17.56M* | (m) | $14.72M | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | -$23.31M | (m) | (m) | (m) | $37.00K | -$13.61M | (m) | $16.82M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$21.91M | (m) | (m) | (m) | $20.00K* | -$12.37M* | (m) | $16.98M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$18.27M | (m) | (m) | (m) | $17.00K* | -$14.39M* | (m) | $14.09M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$17.86M | (m) | (m) | (m) | $5.00K | -$10.78M | (m) | $14.38M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$10.57M | (m) | (m) | (m) | $26.00K* | -$8.80M* | (m) | $8.25M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$9.57M | (m) | (m) | (m) | -$31.00K* | -$6.32M* | (m) | $7.11M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$6.08M | (m) | (m) | (m) | $51.00K | -$7.22M | (m) | $4.83M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$2.87M | (m) | (m) | (m) | $198.00K* | -$1.93M* | (m) | $2.29M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$2.64M | (m) | (m) | (m) | (m) | -$2.62M* | (m) | $2.29M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$2.76M | (m) | (m) | (m) | (m) | -$3.18M | (m) | $2.41M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$58.07M | (m) | (m) | (m) | $352.00K | -$41.42M | (m) | $35.38M | (m) | $3.21M |
| 2024-12-31 | Reported | (m) | -$57.28M | (m) | (m) | (m) | $257.00K | -$31.90M | (m) | $18.59M | (m) | $87.00K |
| 2023-12-31 | Reported | (m) | -$34.62M | (m) | (m) | (m) | $160.00K | -$18.29M | (m) | $9.45M | (m) | -$197.00K |
| 2022-12-31 | Reported | (m) | -$52.02M | (m) | (m) | (m) | $133.00K | -$44.04M | (m) | $25.18M | (m) | -$284.00K |
| 2021-12-31 | Reported | (m) | -$90.32M | (m) | (m) | (m) | $180.00K | -$62.93M | (m) | $60.80M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$78.89M | (m) | (m) | (m) | $52.00K | -$50.82M | (m) | $61.31M | (m) | $0.00 |
| 2019-12-31 | Reported | (m) | -$39.17M | (m) | (m) | (m) | $55.00K | -$33.28M | (m) | $30.21M | (m) | $0.00 |
| 2018-12-31 | Reported | (m) | -$12.12M | (m) | (m) | (m) | $212.00K | -$11.70M | (m) | $10.09M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |